Please note: The information displayed on this page might be outdated.
OnKure Therapeutics, Inc.: OnKure is a private development stage company focusing on epigenetic therapies for cancers including selective inhibitors of HDACs. The Company has reassembled the Array Biopharma team to develop their assets. Lead asset OKI-179 is a class 1 HDAC inhibitor currently in Ph 1.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Mountain
Clinical Stage
Phase l or ll
Disease Space
Oncology
Listing
Private
Market Cap
Private
Website:
Address:
1105 Spruce Street
Boulder, CO 80302
United States

Company Participants at Solebury Trout Virtual Global Healthcare Conference Series

  • Anthony D. Piscopio, Ph.D, President & CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.